pharma · Chronic Spontaneous Urticaria · Asthma
Novartis India
Novartis Pharmaceuticals
Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaP
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
CIAG933A12101
Phase 1 · other · Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway
CIAG933A12101 for Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway is a Phase 1 program (other) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code CIAG933A12101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 1
- Modality
- other
- Indication
- Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway
- Status
- active
- Trials
- 1